Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. 2012

Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
1st Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany.

BACKGROUND Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC). METHODS OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological parameters of HCCs. RESULTS Real time PCR showed a downregulation of SLC22A1 and SLC22A3 in HCC compared to TST (p ≤ 0.001). A low SLC22A1 expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, SLC22A1 was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p < 0.001) and liver transplantation (p = 0.001). Tumors with a low SLC22A1 expression (< median) showed a higher SLC22A3 expression compared to HCC with high SLC22A1 expression (p < 0.001). However, there was no significant difference in tumor characteristics according to the level of the SLC22A3 expression.In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC. CONCLUSIONS The downregulation of OCT1 is associated with tumor progression and a worse patient survival.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
October 2009, Hepatology (Baltimore, Md.),
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
December 2011, Genome medicine,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
April 2013, Molecular pharmaceutics,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
January 2010, Journal of pharmacological sciences,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
June 2013, Antimicrobial agents and chemotherapy,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
May 2010, Annals of medicine,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
January 2004, The Journal of pharmacology and experimental therapeutics,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
December 2008, American journal of physiology. Gastrointestinal and liver physiology,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
November 2003, Molecular and cellular biology,
Michael Heise, and Anja Lautem, and Johanna Knapstein, and Jörn M Schattenberg, and Maria Hoppe-Lotichius, and Daniel Foltys, and Nina Weiler, and Anca Zimmermann, and Arno Schad, and Dirk Gründemann, and Gerd Otto, and Peter R Galle, and Marcus Schuchmann, and Tim Zimmermann
September 2009, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!